Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas.
Desjardins A, Reardon DA, Herndon JE 2nd, Marcello J, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Sampson J, Bailey L, Bigner DD, Friedman AH, Friedman HS, Vredenburgh JJ.
Desjardins A, et al. Among authors: marcello j.
Clin Cancer Res. 2008 Nov 1;14(21):7068-73. doi: 10.1158/1078-0432.CCR-08-0260.
Clin Cancer Res. 2008.
PMID: 18981004
Free PMC article.
Clinical Trial.